Skip to main content

Table 4 Sequential measurements of clinical efficacy outcomes

From: Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial

Variables Baseline Week 1 Week 2 Week 6 Week 12 Week 24
Estimated marginal means (SE)
HDRS
 Mirtazapine 23.0 (1.2) 19.0 (1.3) 15.5 (1.3) 9.6 (1.4) 9.3 (1.5) 5.9 (1.6)
 SSRIs 23.1 (0.9) 19.2 (0.9) 16.9 (0.9) 12.9 (1.0) 9.5 (1.0) 5.4 (1.1)
  Sertraline 23.2 (1.1) 19.1 (1.2) 16.3 (1.1) 12.1 (1.2) 8.7 (1.3) 5.3 (1.4)
  Paroxetine 22.9 (1.5) 19.4 (1.5) 17.8 (1.5) 14.6 (1.7) 11.2 (1.8) 5.8 (2.0)
SDS
 Mirtazapine 56.0 (1.7) 52.4 (1.8) 46.6 (1.8) 44.0 (1.9) 43.7 (2.1) 38.0 (2.2)
 SSRIs 57.6 (1.3) 54.8 (1.3) 52.8 (1.3) 48.7 (1.4) 44.9 (1.5) 41.8 (1.6)
  Sertraline 57.4 (1.6) 54.1 (1.7) 51.2 (1.6) 47.2 (1.7) 42.4 (1.8) 40.3 (1.9)
  Paroxetine 57.9 (2.1) 56.1 (2.1) 55.0 (2.1) 51.4 (2.3) 49.8 (2.5) 44.5 (2.8)
AIS
 Mirtazapine 11.5 (0.9) 8.4 (0.9) 6.6 (0.9) 5.8 (1.0) 6.8 (1.1) 5.0 (1.1)
 SSRIs 12.9 (0.6) 10.2 (0.6) 9.3 (0.6) 7.5 (0.7) 6.6 (0.7) 5.5 (0.8)
  Sertraline 12.8 (0.8) 10.0 (0.8) 8.1 (0.8) 6.9 (0.8) 5.3 (0.9) 4.6 (1.0)
  Paroxetine 13.1 (1.0) 10.5 (1.0) 11.3 (1.0) 8.8 (1.2) 9.2 (1.2) 7.2 (1.4)
CGI-S
 Mirtazapine 4.4 (0.2) 3.8 (0.2) 3.2 (0.2) 2.8 (0.2) 2.6 (0.2) 1.8 (0.2)
 SSRIs 4.3 (0.1) 4.0 (0.1) 3.6 (0.1) 3.1 (0.1) 2.7 (0.1) 2.1 (0.2)
  Sertraline 4.4 (0.2) 4.0 (0.2) 3.6 (0.2) 3.0 (0.2) 2.6 (0.2) 2.1 (0.2)
  Paroxetine 4.2 (0.2) 4.1 (0.2) 3.6 (0.2) 3.5 (0.2) 3.0 (0.3) 2.0 (0.3)
  1. All values are based on estimated marginal means using a linear mixed effects model for repeated measures data
  2. SSRI selective serotonin reuptake inhibitor, HDRS 17-item Hamilton depression rating scale, SDS Zung self-rating depression scale, AIS Athens insomnia scale, SE standard error